Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Depreciation & Amortization (CF) (2016 - 2025)

United Therapeutics (UTHR) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $22.8 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 15.74% to $22.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.6 million through Dec 2025, up 18.07% year-over-year, with the annual reading at $85.6 million for FY2025, 18.07% up from the prior year.
  • Depreciation & Amortization (CF) hit $22.8 million in Q4 2025 for United Therapeutics, up from $21.9 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $22.8 million in Q4 2025 to a low of $12.4 million in Q2 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $15.6 million across 5 years, with a median of $13.3 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): decreased 3.82% in 2021 and later soared 44.96% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $12.6 million in 2021, then rose by 4.76% to $13.2 million in 2022, then rose by 3.79% to $13.7 million in 2023, then skyrocketed by 43.8% to $19.7 million in 2024, then increased by 15.74% to $22.8 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for UTHR at $22.8 million in Q4 2025, $21.9 million in Q3 2025, and $21.1 million in Q2 2025.